Cutaneous melanoma: From pathogenesis to therapy (Review)
- Authors:
- Giulia C. Leonardi
- Luca Falzone
- Rossella Salemi
- Antonino Zanghì
- Demetrios A. Spandidos
- James A. Mccubrey
- Saverio Candido
- Massimo Libra
-
Affiliations: Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy, Department of Medical and Surgical Sciences and Advanced Technology ‘G.F. Ingrassia’, University of Catania, 95125 Catania, Italy, Laboratory of Clinical Virology, Medical School, University of Crete, 71003 Heraklion, Crete, Greece, Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC 27858, USA - Published online on: February 27, 2018 https://doi.org/10.3892/ijo.2018.4287
- Pages: 1071-1080
-
Copyright: © Leonardi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Ali Z, Yousaf N and Larkin J: Melanoma epidemiology, biology and prognosis. EJC Suppl. 11:81–91. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar | |
|
Rastrelli M, Tropea S, Rossi CR and Alaibac M: Melanoma: Epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo. 28:1005–1011. 2014.PubMed/NCBI | |
|
Gilchrest BA, Eller MS, Geller AC and Yaar M: The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med. 340:1341–1348. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Pennello G, Devesa S and Gail M: Association of surface ultraviolet B radiation levels with melanoma and nonmelanoma skin cancer in United States blacks. Cancer Epidemiol Biomarkers Prev. 9:291–297. 2000.PubMed/NCBI | |
|
Falzone L, Marconi A, Loreto C, Franco S, Spandidos DA and Libra M: Occupational exposure to carcinogens: Benzene, pesticides and fibers (Review). Mol Med Rep. 14:4467–4474. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Nelemans PJ, Groenendal H, Kiemeney LA, Rampen FH, Ruiter DJ and Verbeek AL: Effect of intermittent exposure to sunlight on melanoma risk among indoor workers and sun-sensitive individuals. Environ Health Perspect. 101:252–255. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Elwood JM and Jopson J: Melanoma and sun exposure: An overview of published studies. Int J Cancer. 73:198–203. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Candido S, Rapisarda V, Marconi A, Malaponte G, Bevelacqua V, Gangemi P, Scalisi A, McCubrey JA, Maestro R, Spandidos DA, et al: Analysis of the B-RafV600E mutation in cutaneous melanoma patients with occupational sun exposure. Oncol Rep. 31:1079–1082. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P and Melchi CF: Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 41:45–60. 2005. View Article : Google Scholar | |
|
White E, Kirkpatrick CS and Lee JA: Case-control study of malignant melanoma in Washington state. I. Constitutional factors and sun exposure. Am J Epidemiol. 139:857–868. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Lazovich D, Vogel RI, Berwick M, Weinstock MA, Anderson KE and Warshaw EM: Indoor tanning and risk of melanoma: A case-control study in a highly exposed population. Cancer Epidemiol Biomarkers Prev. 19:1557–1568. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Archier E, Devaux S, Castela E, Gallini A, Aubin F, Le Maître M, Aractingi S, Bachelez H, Cribier B, Joly P, et al: Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: A systematic literature review. J Eur Acad Dermatol Venereol. 26(Suppl 3): 22–31. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
International Agency for Research on Cancer Working Group on artificial ultraviolet (UV) light and skin cancer: The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: A systematic review. Int J Cancer. 120:1116–1122. 2007. | |
|
Wehner MR, Chren MM, Nameth D, Choudhry A, Gaskins M, Nead KT, Boscardin WJ and Linos E: International prevalence of indoor tanning: A systematic review and meta-analysis. JAMA Dermatol. 150:390–400. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Bauer J and Garbe C: Acquired melanocytic nevi as risk factor for melanoma development. A comprehensive review of epidemiological data. Pigment Cell Res. 16:297–306. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Russo AE, Torrisi E, Bevelacqua Y, Perrotta R, Libra M, McCubrey JA, Spandidos DA, Stivala F and Malaponte G: Melanoma: Molecular pathogenesis and emerging target therapies (Review). Int J Oncol. 34:1481–1489. 2009.PubMed/NCBI | |
|
Hawkes JE, Truong A and Meyer LJ: Genetic predisposition to melanoma. Semin Oncol. 43:591–597. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Bevona C, Goggins W, Quinn T, Fullerton J and Tsao H: Cutaneous melanomas associated with nevi. Arch Dermatol. 139:1620–1624; discussion 1624. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Seykora J and Elder D: Dysplastic nevi and other risk markers for melanoma. Semin Oncol. 23:682–687. 1996.PubMed/NCBI | |
|
Watt AJ, Kotsis SV and Chung KC: Risk of melanoma arising in large congenital melanocytic nevi: A systematic review. Plast Reconstr Surg. 113:1968–1974. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Gandini S, Sera F, Cattaruzza MS, Pasquini P, Abeni D, Boyle P and Melchi CF: Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer. 41:28–44. 2005. View Article : Google Scholar | |
|
Olsen CM, Zens MS, Stukel TA, Sacerdote C, Chang YM, Armstrong BK, Bataille V, Berwick M, Elwood JM, Holly EA, et al: Nevus density and melanoma risk in women: A pooled analysis to test the divergent pathway hypothesis. Int J Cancer. 124:937–944. 2009. View Article : Google Scholar : | |
|
Dessinioti C, Antoniou C, Katsambas A and Stratigos AJ: Melanocortin 1 receptor variants: Functional role and pigmentary associations. Photochem Photobiol. 87:978–987. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Goldstein AM and Tucker MA: Genetic epidemiology of cutaneous melanoma: A global perspective. Arch Dermatol. 137:1493–1496. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Soura E, Eliades PJ, Shannon K, Stratigos AJ and Tsao H: Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome. J Am Acad Dermatol. 74:395–407; quiz 408–410. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Gruis NA, van der Velden PA, Sandkuijl LA, Prins DE, Weaver-Feldhaus J, Kamb A, Bergman W and Frants RR: Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat Genet. 10:351–353. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, Hayward N and Dracopoli NC: Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet. 12:97–99. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Kanitakis J: Anatomy, histology and immunohistochemistry of normal human skin. Eur J Dermatol. 12:390–399; quiz 400–401. 2002.PubMed/NCBI | |
|
Lin JY and Fisher DE: Melanocyte biology and skin pigmentation. Nature. 445:843–850. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE, et al: Distinct sets of genetic alterations in melanoma. N Engl J Med. 353:2135–2147. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Bastian BC: The molecular pathology of melanoma: An integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol. 9:239–271. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Shain AH and Bastian BC: From melanocytes to melanomas. Nat Rev Cancer. 16:345–358. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, et al: High frequency of BRAF mutations in nevi. Nat Genet. 33:19–20. 2003. View Article : Google Scholar | |
|
Leonardi GC, Accardi G, Monastero R, Nicoletti F and Libra M: Ageing: From inflammation to cancer. Immun Ageing. 15:12018. View Article : Google Scholar : PubMed/NCBI | |
|
Speeckaert R, van Geel N, Vermaelen KV, Lambert J, Van Gele M, Speeckaert MM and Brochez L: Immune reactions in benign and malignant melanocytic lesions: Lessons for immunotherapy. Pigment Cell Melanoma Res. 24:334–344. 2011. View Article : Google Scholar | |
|
Gray-Schopfer V, Wellbrock C and Marais R: Melanoma biology and new targeted therapy. Nature. 445:851–857. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Farmer ER, Gonin R and Hanna MP: Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. Hum Pathol. 27:528–531. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Chiriboga L, Meehan S, Osman I, Glick M, de la Cruz G, Howell BS, Friedman-Jiménez G, Schneider RJ and Jamal S: Endothelin-1 in the tumor microenvironment correlates with melanoma invasion. Melanoma Res. 26:236–244. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Moro N, Mauch C and Zigrino P: Metalloproteinases in melanoma. Eur J Cell Biol. 93:23–29. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Sandri S, Faião-Flores F, Tiago M, Pennacchi PC, Massaro RR, Alves-Fernandes DK, Berardinelli GN, Evangelista AF, de Lima Vazquez V, Reis RM and Maria-Engler SS: Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation. Pharmacol Res. 111:523–533. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Falzone L, Salemi R, Travali S, Scalisi A, McCubrey JA, Candido S and Libra M: MMP-9 overexpression is associated with intragenic hypermethylation of MMP9 gene in melanoma. Aging (Albany NY). 8:933–944. 2016. View Article : Google Scholar | |
|
Lee KR, Lee JS, Kim YR, Song IG and Hong EK: Polysaccharide from Inonotus obliquus inhibits migration and invasion in B16-F10 cells by suppressing MMP-2 and MMP-9 via downregulation of NF-κB signaling pathway. Oncol Rep. 31:2447–2453. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Guarneri C, Bevelacqua V, Polesel J, Falzone L, Cannavò PS, Spandidos DA, Malaponte G and Libra M: NF-κB inhibition is associated with OPN/MMP 9 downregulation in cutaneous melanoma. Oncol Rep. 37:737–746. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr and Kinzler KW: Cancer genome landscapes. Science. 339:1546–1558. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Akbani R, Akdemir KC, Aksoy BA, Albert M, Ally A, Amin SB, Arachchi H, Arora A, Auman JT, Ayala B, et al: Cancer Genome Atlas Network: Genomic classification of cutaneous melanoma. Cell. 161:1681–1696. 2015. View Article : Google Scholar | |
|
Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, et al: A landscape of driver mutations in melanoma. Cell. 150:251–263. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, Cheng E, Davis MJ, Goh G, Choi M, et al: Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet. 44:1006–1014. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Bäsecke J, Stivala F, Donia M, Fagone P, et al: Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: Rationale and importance to inhibiting these pathways in human health. Oncotarget. 2:135–164. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wellbrock C, Karasarides M and Marais R: The RAF proteins take centre stage. Nat Rev Mol Cell Biol. 5:875–885. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Raman M, Chen W and Cobb MH: Differential regulation and properties of MAPKs. Oncogene. 26:3100–3112. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Carlino MS, Long GV, Kefford RF and Rizos H: Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma. Crit Rev Oncol Hematol. 96:385–398. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan TL and Cantley LC: PI3K pathway alterations in cancer: Variations on a theme. Oncogene. 27:5497–5510. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Davies MA: The role of the PI3K-AKT pathway in melanoma. Cancer J. 18:142–147. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Cohen C, Zavala-Pompa A, Sequeira JH, Shoji M, Sexton DG, Cotsonis G, Cerimele F, Govindarajan B, Macaron N and Arbiser JL: Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin Cancer Res. 8:3728–3733. 2002.PubMed/NCBI | |
|
Wang YF, Jiang CC, Kiejda KA, Gillespie S, Zhang XD and Hersey P: Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. Clin Cancer Res. 13:4934–4942. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, Hucks D, Berry E, Terry C, Duke M, et al: Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One. 7:e353092012. View Article : Google Scholar : PubMed/NCBI | |
|
Rubinstein JC, Sznol M, Pavlick AC, Ariyan S, Cheng E, Bacchiocchi A, Kluger HM, Narayan D and Halaban R: Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med. 8:672010. View Article : Google Scholar : PubMed/NCBI | |
|
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al: Mutations of the BRAF gene in human cancer. Nature. 417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Wan PTC, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D and Marais R; Cancer Genome Project: Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 116:855–867. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Richtig G, Hoeller C, Kashofer K, Aigelsreiter A, Heinemann A, Kwong LN, Pichler M and Richtig E: Beyond the BRAFV600E hotspot: Biology and clinical implications of rare BRAF gene mutations in melanoma patients. Br J Dermatol. 177:936–944. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Kim KB, et al: NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 118:4014–4023. 2012. View Article : Google Scholar : | |
|
Giehl K: Oncogenic Ras in tumour progression and metastasis. Biol Chem. 386:193–205. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Fedorenko IV, Gibney GT and Smalley KS: NRAS mutant melanoma: Biological behavior and future strategies for therapeutic management. Oncogene. 32:3009–3018. 2013. View Article : Google Scholar | |
|
Maertens O, Johnson B, Hollstein P, Frederick DT, Cooper ZA, Messiaen L, Bronson RT, McMahon M, Granter S, Flaherty K, et al: Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov. 3:338–349. 2013. View Article : Google Scholar : | |
|
Whittaker SR, Theurillat JP, Van Allen E, Wagle N, Hsiao J, Cowley GS, Schadendorf D, Root DE and Garraway LA: A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov. 3:350–362. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Nissan MH, Pratilas CA, Jones AM, Ramirez R, Won H, Liu C, Tiwari S, Kong L, Hanrahan AJ, Yao Z, et al: Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res. 74:2340–2350. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Krauthammer M, Kong Y, Bacchiocchi A, Evans P, Pornputtapong N, Wu C, McCusker JP, Ma S, Cheng E, Straub R, et al: Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat Genet. 47:996–1002. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Gibney GT and Smalley KS: An unholy alliance: Cooperation between BRAF and NF1 in melanoma development and BRAF inhibitor resistance. Cancer Discov. 3:260–263. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J, Town A, Harlow A, Cruz F III, Azar S, et al: KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res. 14:6821–6828. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Handolias D, Salemi R, Murray W, Tan A, Liu W, Viros A, Dobrovic A, Kelly J and McArthur GA: Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. Pigment Cell Melanoma Res. 23:210–215. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, Dummer R, North J, Pincus L, Ruben B, et al: The genetic evolution of melanoma from precursor lesions. N Engl J Med. 373:1926–1936. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Castellano M, Pollock PM, Walters MK, Sparrow LE, Down LM, Gabrielli BG, Parsons PG and Hayward NK: CDKN2A/16 is inactivated in most melanoma cell lines. Cancer Res. 57:4868–4875. 1997.PubMed/NCBI | |
|
Sharpless E and Chin L: The INK4a/ARF locus and melanoma. Oncogene. 22:3092–3098. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Wu H, Goel V and Haluska FG: PTEN signaling pathways in melanoma. Oncogene. 22:3113–3122. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Mirmohammadsadegh A, Marini A, Nambiar S, Hassan M, Tannapfel A, Ruzicka T and Hengge UR: Epigenetic silencing of the PTEN gene in melanoma. Cancer Res. 66:6546–6552. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Stahl JM, Cheung M, Sharma A, Trivedi NR, Shanmugam S and Robertson GP: Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res. 63:2881–2890. 2003.PubMed/NCBI | |
|
Tsao H, Goel V, Wu H, Yang G and Haluska FG: Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol. 122:337–341. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Nogueira C, Kim KH, Sung H, Paraiso KH, Dannenberg JH, Bosenberg M, Chin L and Kim M: Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene. 29:6222–6232. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, et al: Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 4:80–93. 2014. View Article : Google Scholar : | |
|
Damsky WE, Curley DP, Santhanakrishnan M, Rosenbaum LE, Platt JT, Gould Rothberg BE, Taketo MM, Dankort D, Rimm DL, McMahon M and Bosenberg M: β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell. 20:741–754. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Rimm DL, Caca K, Hu G, Harrison FB and Fearon ER: Frequent nuclear/cytoplasmic localization of β-catenin without exon 3 mutations in malignant melanoma. Am J Pathol. 154:325–329. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Ross MI and Gershenwald JE: Evidence-based treatment of early-stage melanoma. J Surg Oncol. 104:341–353. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Luke JJ, Flaherty KT, Ribas A and Long GV: Targeted agents and immunotherapies: Optimizing outcomes in melanoma. Nat Rev Clin Oncol. 14:463–482. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, et al: Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet. 380:358–365. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, et al: Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 15:323–332. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, et al: Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 372:320–330. 2015. View Article : Google Scholar | |
|
Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, et al: Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 372:30–39. 2015. View Article : Google Scholar | |
|
Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, et al: Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 386:444–451. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, et al: Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial. Lancet Oncol. 16:908–918. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani I, Miller WH Jr, Lao CD, et al: Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16:375–384. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, et al: Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): Updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 17:1248–1260. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Malas S, Harrasser M, Lacy KE and Karagiannis SN: Antibody therapies for melanoma: New and emerging opportunities to activate immunity (Review). Oncol Rep. 32:875–886. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Song Y and Gao Q: Increased survival time of a patient with metastatic malignant melanoma following immunotherapy: A case report and literature review. Oncol Lett. 10:883–886. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Akiyama Y, Nonomura C, Kondou R, Miyata H, Ashizawa T, Maeda C, Mitsuya K, Hayashi N, Nakasu Y and Yamaguchi K: Immunological effects of the anti-programmed death-1 antibody on human peripheral blood mononuclear cells. Int J Oncol. 49:1099–1107. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Larkin J, Lao CD, Urba WJ, McDermott DF, Horak C, Jiang J and Wolchok JD: Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: A pooled analysis of 4 clinical trials. JAMA Oncol. 1:433–440. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Mangana J, Cheng PF, Schindler K, Weide B, Held U, Frauchiger AL, Romano E, Kähler KC, Rozati S, Rechsteiner M, et al: Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA 4 antibodies: Association with overall survival. PLoS One. 10:e01394382015. View Article : Google Scholar | |
|
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al KEYNOTE-006 investigators: Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 372:2521–2532. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Simeone E and Ascierto PA: Immunomodulating antibodies in the treatment of metastatic melanoma: The experience with anti-CTLA-4, anti-CD137, and anti-PD1. J Immunotoxicol. 9:241–247. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A, Gutzmer R, Schlaak M, Heinzerling L, Krackhardt AM, Loquai C, et al: Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. Eur J Cancer. 75:47–55. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
McCubrey JA, Steelman LS, Kempf CR, Chappell WH, Abrams SL, Stivala F, Malaponte G, Nicoletti F, Libra M, Bäsecke J, et al: Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol. 226:2762–2781. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, et al: Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY). 3:192–222. 2011. View Article : Google Scholar | |
|
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S, Malaponte G, et al: Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: How mutations can result in therapy resistance and how to overcome resistance. Oncotarget. 3:1068–1111. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, Place CS, Taylor-Weiner A, Whittaker S, Kryukov GV, et al Dermatologic Cooperative Oncology Group of Germany (DeCOG): The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 4:94–109. 2014. View Article : Google Scholar : | |
|
Hugo W, Shi H, Sun L, Piva M, Song C, Kong X, Moriceau G, Hong A, Dahlman KB, Johnson DB, et al: Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell. 162:1271–1285. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Gray ES, Rizos H, Reid AL, Boyd SC, Pereira MR, Lo J, Tembe V, Freeman J, Lee JH, Scolyer RA, et al: Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget. 6:42008–42018. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Santiago-Walker A, Gagnon R, Mazumdar J, Casey M, Long GV, Schadendorf D, Flaherty K, Kefford R, Hauschild A, Hwu P, et al: Correlation of BRAF Mutation status in circulating-free dna and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials. Clin Cancer Res. 22:567–574. 2016. View Article : Google Scholar | |
|
Girotti MR, Gremel G, Lee R, Galvani E, Rothwell D, Viros A, Mandal AK, Lim KH, Saturno G, Furney SJ, et al: Application of sequencing, liquid biopsies, and patient-derived xenografts for personalized medicine in melanoma. Cancer Discov. 6:286–299. 2016. View Article : Google Scholar | |
|
Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT and Gajewski TF: Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 5:200ra1162013. View Article : Google Scholar : PubMed/NCBI | |
|
Donia M, Harbst K, van Buuren M, Kvistborg P, Lindberg MF, Andersen R, Idorn M, Munir Ahmad S, Ellebæk E, Mueller A, et al: Acquired immune resistance follows complete tumor regression without loss of target antigens or IFNγ signaling. Cancer Res. 77:4562–4566. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Spranger S, Bao R and Gajewski TF: Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature. 523:231–235. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, et al: Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Disco. 6:202–216. 2016. View Article : Google Scholar | |
|
Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, et al: Mutations associated with acquired resistance to PD 1 blockade in melanoma. N Engl J Med. 375:819–829. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Banna GL, Torino F, Marletta F, Santagati M, Salemi R, Cannarozzo E, Falzone L, Ferraù F and Libra M: Lactobacillus rhamnosus GG: An overview to explore the rationale of its use in cancer. Front Pharmacol. 1(8): 6032017. View Article : Google Scholar | |
|
Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, et al: Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 359:97–103. 2018. View Article : Google Scholar | |
|
Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, et al: Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 359:91–97. 2018. View Article : Google Scholar | |
|
Pappalardo F, Russo G, Candido S, Pennisi M, Cavalieri S, Motta S, McCubrey JA, Nicoletti F and Libra M: Computational modeling of PI3K/AKT and MAPK signaling pathways in melanoma Cancer. PLoS One. 11:e01521042016. View Article : Google Scholar : PubMed/NCBI | |
|
Rambow F, Job B, Petit V, Gesbert F, Delmas V, Seberg H, Meurice G, Van Otterloo E, Dessen P, Robert C, et al: New functional signatures for understanding melanoma biology from tumor cell lineage-specific analysis. Cell Reports. 13:840–853. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Pennisi M, Russo G, Di Salvatore V, Candido S, Libra M and Pappalardo F: Computational modeling in melanoma for novel drug discovery. Expert Opin Drug Discov. 11:609–621. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al BRIM-3 Study Group: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 364:2507–2516. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 364:2517–2526. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, et al: Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 377:1345–1356. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al: Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 390:1853–1862. 2017. View Article : Google Scholar : PubMed/NCBI |
